Abstract: NCT03134872.
Introduction
The 5-year update of the CameL phase 3 study provides critical long-term evidence for the efficacy of camrelizumab, an anti-PD-1 antibody, in combination with standard chemotherapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Historically, advanced NSCLC carried a poor prognosis; however, this study demonstrates a durable survival benefit, with nearly one-third of patients in the combination group alive at the five-year mark—a significant milestone in the treatment of this disease.
Study Design and Methodology
The CameL study was a randomized, open-label, multicenter phase 3 trial involving 412 patients across 52 sites in China. Participants with previously untreated, advanced non-squamous NSCLC without EGFR or ALK mutations were randomized to receive either:
- Experimental Arm: Camrelizumab + Carboplatin + Pemetrexed (n=205)
- Control Arm: Carboplatin + Pemetrexed alone (n=207)
Patients received 4–6 cycles of the combination therapy followed by maintenance. Notably, the trial allowed for crossover, permitting patients in the chemotherapy-only group to receive camrelizumab monotherapy upon disease progression. To account for the potential confounding effect of crossover on survival data, researchers utilized a Rank-Preserving Structural Failure Time (RPSFT) model to calculate adjusted Hazard Ratios (HR).
Key Results
The 5-year analysis, with a median follow-up of 65.2 months, confirms the sustained superiority of the camrelizumab combination over chemotherapy alone.
Overall Survival (OS)
The median OS was significantly longer in the combination group (27.1 months) compared to the chemotherapy group (19.8 months), representing a Hazard Ratio of 0.74. When adjusted for crossover using the RPSFT model, the HR improved to 0.62. Most importantly, the 5-year OS rate was 31.2% for the combination arm versus 19.3% for the control arm.
Progression-Free Survival and Response Durability
The 5-year Progression-Free Survival (PFS) rate was 16.1% for the combination group, compared to just 3.0% for the chemotherapy group. Furthermore, the duration of response (DoR) highlights the persistence of the treatment effect: the 5-year DoR rate was 21.3% in the combination group, whereas no patients in the chemotherapy-only group maintained a response for five years.
Clinical Insights
The "Survival Tail" and Long-term Responders
The Kaplan-Meier curves for OS exhibit a distinct "tail," where the survival probability flattens after approximately three years. This indicates that a subset of patients achieves long-term, stable disease control. A particularly striking finding was observed in the "2-year completers"—the 33 patients who finished the maximum permitted 2 years of camrelizumab. In this cohort, the 5-year OS rate reached an extraordinary 84.3%, suggesting that two years of therapy may be sufficient to "reset" the immune system in responders.
Impact of Crossover
Despite a high effective crossover rate (52.7% of the chemotherapy group eventually received immunotherapy), the first-line combination group maintained a statistically significant survival advantage. This underscores the importance of utilizing immune checkpoint inhibitors in the first-line setting rather than reserving them for second-line treatment.
Safety and Tolerability
The long-term safety profile remained manageable, with no new or late-onset safety signals identified. Reactive cutaneous capillary endothelial proliferation (RCCEP), a skin-related side effect characteristic of camrelizumab, was the most common immune-mediated event but was primarily Grade 1-2 and self-limiting.
Conclusion
The CameL study establishes camrelizumab plus chemotherapy as a potent first-line option for advanced non-squamous NSCLC, offering a substantial chance for 5-year survival. While the study was conducted in a Chinese population, the results contribute significantly to the global understanding of long-term ICI efficacy. Future research will focus on identifying biomarkers to better predict long-term survivors and exploring optimal treatment durations for patients who do not achieve a complete response within the initial two years.
Summary updated